Intellia Therapeutics Inc
NASDAQ:NTLA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.02
32.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intellia Therapeutics Inc
Intellia Therapeutics Inc
Depreciation & Amortization
Intellia Therapeutics Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Intellia Therapeutics Inc
NASDAQ:NTLA
|
Depreciation & Amortization
$9.9m
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
34%
|
CAGR 10-Years
27%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
$5.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
23%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$219.7m
|
CAGR 3-Years
22%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$469.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
19%
|
CAGR 10-Years
25%
|
|
Intellia Therapeutics Inc
Glance View
In the rapidly evolving landscape of biotechnology, Intellia Therapeutics Inc. stands as a pioneer, relentlessly forging new frontiers in the realm of genome editing. At its core, the company's mission revolves around harnessing the revolutionary CRISPR/Cas9 technology to develop therapies that can potentially cure genetic diseases at their source. Intellia's approach centers on the direct genetic modification of specific cells within the body, aiming to address the root cause of diseases rather than merely managing symptoms. This innovative method marks a significant departure from traditional therapies, leveraging the power of CRISPR/Cas9—a sophisticated gene-editing tool that can be tailored to precisely alter DNA within living organisms. The company focuses on in vivo treatments, which allow for the editing of genes within the body, and ex vivo strategies, where cells are edited outside the body and then reintroduced, targeting a variety of ailments ranging from liver diseases to blood disorders. Financially, Intellia's business model is anchored in a strategic blend of collaborative partnerships and internal research initiatives. The company generates revenue through alliances with established pharmaceutical giants, enabling the co-development of CRISPR-based therapies. These partnerships not only provide significant upfront payments and milestone-based funding but also secure Intellia a share of potential future profits. Additionally, the company invests heavily in its pipeline of proprietary programs, with a keen focus on advancing its lead therapeutics through rigorous clinical trials. By aligning its scientific prowess with a robust commercial strategy, Intellia seeks to ensure a steady revenue stream while advancing its ambition to transform the landscape of genetic medicine. In doing so, it maintains a vital balance between innovation and sustainability, striving to turn cutting-edge science into practical, life-altering medical solutions.
See Also
What is Intellia Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
9.9m
USD
Based on the financial report for Sep 30, 2024, Intellia Therapeutics Inc's Depreciation & Amortization amounts to 9.9m USD.
What is Intellia Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
14%
Over the last year, the Depreciation & Amortization growth was 16%. The average annual Depreciation & Amortization growth rates for Intellia Therapeutics Inc have been 14% over the past three years , 14% over the past five years .
You don't have any saved screeners yet
